http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905715-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90128edfcd7678c54a90e9604ea594a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da7605315ebebcf586d458e04847524a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13 |
| filingDate | 2017-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0667c77d01ae835d2d2873bfa989914 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec94c8e76c9ee553b996721a4cf8f3dd |
| publicationDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10905715-B2 |
| titleOfInvention | Autologous implantation of chimeric murine-human tumors, generated in PDX mice, for ativation of an anti-tumor immune response in the donor patient |
| abstract | Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in PDX mice, back to the original donor patients. This is an approach to personalized cancer therapy, which does not require identification of specific tumor associated antigens. Based on the fundamental principles of immunology, we anticipate that the autoimplanted PDX tumor will stimulate an intense immune response in the original donor patient—including activation of “xenoreactive” lymphocytes and, in turn, a “bystander” activation of anti-tumor immune response lymphocytes, which we anticipate that a response generated in this manner will become systemic and target other similar malignant cells in the patient. Once such an immune response is activated, it is expected to promote overall regression, or cure, of the malignant state by killing in cancerous cells in the donor cancer patient. |
| priorityDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 136.